Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
QOIL
YOU FORGOT NWBT........
NAPS ON A ROLL TODAY.....
IVE BEEN THERE MANY TIMES WITH PENNY STOCKS AND SAID THE SAME THING AS YOU ....BUT YOU SHOULD KNOW BETTER ....
SEEMS TO ME I HEARD YOU MAKE THAT STATEMENT ABOUT NOT BUYING PENNY STOCKS ABOUT A WEEK OR TWO AGO ......
BIOM
PPHM
A LITTLE PRESS FOR US
http://abcnews.go.com/Health/wireStory?id=640463
# 4 HAD SOME GOOD NEWS LAST NIGHT .....MAYBE READY TO TURN TO THE UPSIDE....
NO PROBLEM JOHN
IM NOT COMPLAINING , IN FACT IM SO UNCONCERNED I'VE BEEN WATCHING THE YANKEES KICK THE RED SOX AROUND ALL AFTERNOON....WIN SOME , LOSE SOME , IF I COME OUT AHEAD IN THE END THATS ALL THAT COUNTS..........JAKE
ACTUALLY JOHN , I GOT IN SOONER BECAUSE OF THIS
http://www.investorshub.com/boards/read_msg.asp?message_id=5908201
BUT IM A BIG BOY AND I DONT HAVE TO SELL RIGHT NOW ...I CAN HOLD FOREVER IF NEED BE BUT I HATE TO TIE UP THE CASH I COULD USE FOR BETTER TRADING OPPORTUNITIES.......JAKE
TOO LATE FOR ME TO WAIT FOR WEAKNESS .IM IN SINCE MONDAY MORNING WHEN IT WAS POSTED AS A MONTHLY.... AT 4.24
# 4 MAJOR DROP ...HANG ON ???
IT FIGURES .NAPS FLYING IN PRE MARKET ....
ASHLEY.....
IVE BEEN IN PPHM SINCE THEY WERE TCLN ..PROBABLY ABOUT 10 YEARS ... IM WHAT YOU CALL A LONG GONE......LOL
LESSON LEARNED, DONT FALL IN LOVE WITH ANY STOCK NO MATTER HOW GOOD THE TECHNOLOGY ESPECIALLY IF THEY HAVENT ANY MONEY .....
PPHM'S TIME WILL COME
TARVACIN IS TOO GOOD ....
WE ARE AT 1.55 NOW
GO FIGURE
ONE MORE RELEASE
National Institute of Allergies and Infectious Diseases to Test Tarvacin(TM) for Antiviral Potential
PR Newswire - April 04, 2005 08:30
Peregrine Pharmaceutical's Anti-Phospholipid Therapy to Be Screened Against Broad Spectrum of Viruses That Threaten Worldwide Health and Global Security
TUSTIN, Calif., April 4, 2005 /PRNewswire-FirstCall via COMTEX/ -- Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM) and the National Institute of Allergy and Infectious Disease (NIAID) have agreed to a collaboration in which NIAID's testing laboratories will screen Peregrine's Anti-Phospholipid Therapy agents, including Tarvacin(TM), for activity against a broad spectrum of enveloped viral pathogens of health and bioterrorism concern. Virus types to be screened as part of the collaboration potentially include herpes viruses, respiratory viruses, pox viruses, Hepatitis B and C, Papillomavirus and viruses of biodefense concern including Pichinde, Yellow Fever, West Nile and Dengue.
"We are very pleased to be able to work with the NIAID to further explore the anti-viral potential of Tarvacin(TM) and the rest of our Anti-Phospholipid Therapy agents," said Steven King, president and CEO of Peregrine Pharmaceuticals. "The data that will be generated from this collaboration will be very helpful in guiding development of our Tarvacin(TM) anti-viral clinical program."
During the first year of an ongoing 3-year, $1.68 million grant from the NIAID, scientists at the University of Texas Southwestern Medical Center at Dallas determined that Tarvacin(TM) binds to virally infected cells and viral particles including Pichinde virus, which causes a fatal viral hemorrhagic fever and is used as an established model for Lassa fever. Pichinde virus is on the U.S. government's biodefense Category A watch list. The researchers further determined that Tarvacin(TM) also significantly protected animals challenged with a lethal dose of Pichinde virus. Results from these studies are being presented at the annual meeting of the American Association of Immunologists taking place this week in San Diego, California.
Pathogens to be screened in this collaboration belong to a class of viruses known as "enveloped viruses," which derive their outermost coating from their host cell membrane during viral replication. Enveloped viruses account for many of the most concerning viral health risks including HIV, Hepatitis B and C, cytomegalovirus, hemorrhagic fever, SARS and various types of influenza including Avian influenza.
About Anti-Phospholipid Therapy in the Treatment of Viral Diseases
Anti-Phospholipid Therapy is Peregrine Pharmaceuticals' novel approach to treating cancer, viral infections and certain ocular diseases. It is based on the finding that aminophospholipids, which are basic components of the inner surface of the cell membrane, become exposed as antigenic targets in certain disease states.
A large number of viruses that impact global health and security possess an "envelope" derived from their host cell membrane. Since viruses lack the means to maintain structural organization of the envelope, amino-phospholipids such as phosphatidylserine (PS) and phosphatidylethanolamine (PE) become exposed on the surface of these viruses, making them potential therapeutic targets. Peregrine Pharmaceuticals, together with its collaborators, has developed a series of monoclonal antibodies directed against aminophospholipids to take advantage of this property.
About the National Institute of Allergies and Infectious Diseases (NIAID)
NIAID is a part of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID conducts and supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, SARS, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a broad portfolio of products under development directed towards the treatment of cancer, viruses and other diseases. Peregrine's viral therapy approach is based on the fact that enveloped viruses and virally infected cells have phospholipids exposed on their surface and thus can be targeted using our APT agents. Our oncology programs are primarily focused on the areas of anti-phospholipid technology, anti-angiogenesis and vascular targeting.
Peregrine Pharmaceuticals also has in-house expertise to develop and manufacture antibodies and recombinant proteins through its wholly-owned subsidiary, Avid Bioservices, Inc., (http://www.avidbio.com). Avid is engaged in providing contract manufacturing services and development of biologics for biopharmaceutical and biotechnology companies, including Peregrine.
Copies of Peregrine Pharmaceuticals press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.peregrineinc.com
PPHM GOING TO BE INTERESTING TODAY
PPHM - Peregrine Pharmaceuticals' Tarvacin(TM) Shows Significant Anti-Viral Activity [DZKDNZN]
SAN DIEGO, April 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that there will be two presentations, April 4 and 6, at the American Association of Immunologists (AAI) annual meeting in San Diego, California, indicating the anti-viral potential of its Tarvacin(TM) antibody. Dr. Melina Soares of The University of Texas Southwestern Medical Center at Dallas will present pre-clinical data titled "Targeting inside-out phospholipids on viruses in a guinea pig model of Lassa fever." The data to be presented demonstrates that Tarvacin(TM) has significant anti-viral activity in the treatment of Pichinde virus, which is an established model for Lassa fever, a fatal viral hemorrhagic fever that is on the U.S. government's biodefense Category A watch list.
Key Study Findings Include:
* Animals lethally infected with Pichinde virus and then treated with
Tarvacin(TM) showed a 50 percent survival rate as compared to zero
survivors in the control treated group.
* Surviving animals did not show any signs of viral infection several
months after treatment with Tarvacin(TM) and were considered to have
been disease free.
* Surviving animals had long-term immunity to further infection with the
Pichinde virus.
* Tarvacin(TM) protected lethally infected animals whether treated at
the time of viral challenge or once symptoms had developed indicating
an active viral infection.
* Tarvacin(TM) binds to both Pichinde viral particles and
Pichinde-infected cells.
"The pre-clinical data demonstrate that Tarvacin(TM) and related Anti-Phospholipid Therapy agents have anti-viral therapy which, if proven out in the clinic, has far reaching implications for the treatment of infectious disease," said Dr. Philip Thorpe, professor of pharmacology at UT Southwestern, and the co-author on the presentations. "Since Tarvacin(TM) targets a basic, universal property of enveloped viruses that is host-derived and independent of the viral genome, it may be effective against a broad spectrum of enveloped viruses. This target may also be difficult for viruses to overcome via resistance mechanisms."
Enveloped viruses account for many of the most concerning viral health risks including HIV, Hepatitis B and C, cytomegalovirus, hemorrhagic fever, SARS and various types of influenza including Avian influenza. The presentations represent a summary of first-year results from an ongoing 3-year, $1.68 million grant from the National Institute of Allergy and Infectious Disease (NIAID), which is part of the National Institutes of Health (NIH). The funded research is investigating the ability of anti-phospholipid antibodies to bind directly to enveloped viruses and to virally infected cells from a number of viruses.
"This data supports a second exciting opportunity for Tarvacin(TM) to accompany the broad anti-cancer activities seen with the same compound," said Steven King, president and CEO of Peregrine. "Because we have a complete IND package for manufacturing and pre-clinical safety of Tarvacin(TM) that was used to support the upcoming Phase I cancer therapy clinical trial, we may be able to initiate clinical evaluation of Tarvacin(TM) in the near future as an anti-viral agent."
About Anti-Phospholipid Therapy in the Treatment of Viral Diseases
Anti-Phospholipid Therapy is Peregrine's novel approach to treating cancer, viral infections and certain ocular diseases. It is based on the finding that aminophospholipids, which are basic components of the inner surface of the cellular membrane, become exposed as antigenic targets in response to certain disease states.
A large number of viruses significant to global health and security possess an "envelope" derived from their host cell membrane. Since viruses lack the means to maintain structural organization of the envelope, amino-phospholipids such as phosphatidylserine (PS) and phosphatidylethanolamine (PE) become exposed on the surface of these viruses, making them a potential therapeutic target. Peregrine, together with its collaborators, has developed a series of monoclonal antibodies directed against aminophospholipids to take advantage of this property.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a broad portfolio of products under development directed towards the treatment of cancer, viruses and other diseases. Our oncology programs are primarily focused on the areas of anti-phospholipid technology, anti-angiogenesis and vascular targeting. We are also investigating potential antiviral applications for our antiphospholipid technology platform through collaborations with UT Southwestern and the National Institute for Allergy and Infectious Disease (NIAID), which is part of the National Institutes of Health.
Peregrine also has in-house expertise to develop and manufacture antibodies and recombinant proteins through its wholly-owned subsidiary, Avid Bioservices, Inc. (http://www.avidbio.com). Avid is engaged in providing contract manufacturing services and development of biologics for biopharmaceutical and biotechnology companies, including Peregrine.
Copies of Peregrine Pharmaceuticals press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.peregrineinc.com
Statements in this press release which are not purely historical including statements regarding Peregrine Pharmaceutical's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the likelihood of consistent survival rates with other viruses in animal models, the timing of submitting an Investigative New Drug application to commence a phase I study using Tarvacin(TM) for viruses, initiating patient enrollment under the Tarvacin(TM) Phase I cancer study in the near term, and continuing to receive assistance from scientists on our Scientific Resource Board in the evaluation of potential ways to use Anti-Phospholipid Therapy agents clinically to treat viral diseases. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing pre-clinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, pre-clinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by all of the foregoing and a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2004, and the quarterly report on Form 10-Q for the quarter ended January 31, 2005. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake, to update or revise any forward-looking statements in this press release.
Investor Inquiries Media Inquiries
Hawk Associates, Inc. Rachel Martin
Frank Hawkins and Ken AuYeung Edelman
(800) 987-8256 (323) 202-1031/(323) 893-9047
info@hawkassociates.com Rachel.Martin@edelman.com
SOURCE Peregrine Pharmaceuticals, Inc.
PERSONALLY I THINK LENF WILL NOW BE THE NEW LEADER IN THIS FIELD....
Pope John Paul II has a high fever caused by an infection in his urinary tract, Vatican spokesman Joaquin Navarro-Valls said, in the latest sign of the ailing pontiff's deteriorating health. Despite his worsening health conditions, Sky Italia quoting Vatican sources said the pope would remain at the Vatican and not be hospitalized for the time being because he is too weak. The pope has been hospitalized twice since February 1. Italian television stations reported that the pope had been given the last rites, but there was no confirmation of the reports.
Terri Schiavo, the brain-damaged Florida woman at the heart of a wrenching legal dispute that drew in Congress and President Bush, died on Thursday, 13 days after her feeding tube was removed by court order. Amid the same glare of publicity and outpouring of bitterness that marked the last days of her life, the 41-year-old woman's body was driven away under heavy police guard to a county medical examiner's office for an autopsy.
KEN.
NICE DAY FOR PPHM ... TOMORROW SHOULD BE EVEN BETTER .. THEY DID A REAL CUTE JOB AT THE LAST TICK DROPPING IT FROM 1.50 TO 1.47 BUT ITS TRADING BACK OVER 1.50 AFTER HOURS .....NEXT WEEK COULD BE VERY PROFITABLE.......JAKE
BLASHER..DOESNT THE E PICK FOR APRIL LOOK BETTER AS A WEEKLY FOR WEEK # 15 ???
LETS MAKE SOME REAL MONEY WOODY....... WE HAVE BEEN WAITING A LONG TIME FOR OUR TIME TO COME.......JAKE
I DONT OWN IT BUT I LOADED UP ON # 3 THIS WEEK ON EVERY DIP..
ALSO HAVE A BUNCH OF LENF
I JUST GOT BACK IN ACTION MYSELF
DOCTOR TOLD ME I HAVE SUGAR LAST WEEK AND THE SECRETARY OF WAR (WIFE) IS KEEPING ME ON A SHORT LEASH FOR NOW ....
I HOPE ITS NOT JUST MOVING WITH TODAYS MARKET ...WOODFOX ???
DO YOU THINK IM WOODFOX ??? NOT ME.....
THERE GOES # 2
PPHM CHART
PPHM STARTING TO MOVE ???
I ONLY POSTED IT BECAUSE I KNEW YOU GOT CAUGHT HOLDING IT LAST WEEK AS I DID TOO.... TO MAKE MATTERS WORSE , I SOLD MINE YESTERDAY AT .20 AND LOST A FEW DOLLARS...
NWBT ON THE MOVE TODAY.
EVERYBODY HAVE A GREAT DAY OFF AND HAPPY EASTER TO ALL
THANKS D-K ...IT WORKED PERFECTLY ....
LENF......
WHEN WILL I LEARN TO TAKE PROFITS .........LOL
GOD I HOPE NOT....LOL
KEN......
WAS IT THE CAPS ??......LOL
PS.....YOUR BETTER THAN DICK TRACEY.......LOL
KEN....LENF NEWS
http://biz.yahoo.com/bw/050323/235011_1.html